XML 64 R55.htm IDEA: XBRL DOCUMENT v3.23.3
Derivative instruments and hedging activities - Summary Of Pre-tax (gains) losses from Derivatives Designated in Cash Flow Hedging Relationships (Detail) - Designated as Hedging Instrument [Member] - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Disclosure In Tabular Form Of Pretax Gain Loss Cash Flow Hedging Instruments [Line Items]        
Other comprehensive income (loss) $ (249) $ (395) $ (156) $ (663)
Cross Currency Swap Cash Flow Hedge [Member]        
Disclosure In Tabular Form Of Pretax Gain Loss Cash Flow Hedging Instruments [Line Items]        
Other comprehensive income (loss) [1] 1 0 (4) 0
Financial Expenses Net [Member]        
Disclosure In Tabular Form Of Pretax Gain Loss Cash Flow Hedging Instruments [Line Items]        
Financial expenses, net 280 252 808 721
Financial Expenses Net [Member] | Cross Currency Swap Cash Flow Hedge [Member]        
Disclosure In Tabular Form Of Pretax Gain Loss Cash Flow Hedging Instruments [Line Items]        
Financial expenses, net [1] $ (7) $ 0 $ (22) $ 0
[1] On March 31, 2023, Teva entered into a cross-currency interest rate swap agreement, designated as cash flow hedge for accounting purposes with respect to an intercompany loan due October 2026, denominated in Japanese yen.